These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35284994)

  • 1. COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab.
    Cross AH; Delgado S; Habek M; Davydovskaya M; Ward BJ; Cree BAC; Totolyan N; Pingili R; Mancione L; Hu X; Sullivan R; Su W; Zielman R; Gupta AD; Montalban X; Winthrop K
    Neurol Ther; 2022 Jun; 11(2):741-758. PubMed ID: 35284994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment.
    Hauser SL; Kappos L; Bar-Or A; Wiendl H; Paling D; Williams M; Gold R; Chan A; Milo R; Das Gupta A; Karlsson G; Sullivan R; Graham G; Merschhemke M; Häring DA; Vermersch P
    Neurol Ther; 2023 Oct; 12(5):1491-1515. PubMed ID: 37450172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
    Hauser SL; Cross AH; Winthrop K; Wiendl H; Nicholas J; Meuth SG; Giacomini PS; Saccà F; Mancione L; Zielman R; Bagger M; Das Gupta A; Häring DA; Jehl V; Kieseier BC; Pingili R; Stoneman D; Su W; Willi R; Kappos L
    Mult Scler; 2022 Sep; 28(10):1576-1590. PubMed ID: 35229668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral immune response to COVID-19 mRNA vaccines in patients with relapsing multiple sclerosis treated with ofatumumab.
    Bar-Or A; Aburashed R; Chinea AR; Hendin BA; Lucassen E; Meng X; Stankiewicz J; Tullman MJ; Cross AH
    Mult Scler Relat Disord; 2023 Nov; 79():104967. PubMed ID: 37769429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world use of ofatumumab to treat multiple sclerosis 9 months post-FDA approval during COVID-19 pandemic.
    Coyle PK; Gorritz M; Wade RL; Zhou Z; Khalid S; Maiese EM; Deshpande C; Shao QS
    Mult Scler Relat Disord; 2023 Oct; 78():104881. PubMed ID: 37556938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension.
    Hauser SL; Zielman R; Das Gupta A; Xi J; Stoneman D; Karlsson G; Robertson D; Cohen JA; Kappos L
    Mult Scler; 2023 Oct; 29(11-12):1452-1464. PubMed ID: 37691530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 in ocrelizumab-treated people with multiple sclerosis.
    Hughes R; Whitley L; Fitovski K; Schneble HM; Muros E; Sauter A; Craveiro L; Dillon P; Bonati U; Jessop N; Pedotti R; Koendgen H
    Mult Scler Relat Disord; 2021 Apr; 49():102725. PubMed ID: 33482590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results on SARS-CoV-2 mRNA Vaccine Booster from an Open-Label Multicenter Study in Ofatumumab-Treated Participants with Relapsing Multiple Sclerosis.
    Ziemssen T; Schlegel E; Groth M; Ettle B; Bopp T
    Vaccines (Basel); 2023 May; 11(5):. PubMed ID: 37243082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab.
    Ziemssen T; Groth M; Ettle B; Bopp T
    Vaccines (Basel); 2022 Dec; 10(12):. PubMed ID: 36560576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosis.
    Kramer J; Linker R; Paling D; Czaplinski A; Hoffmann O; Yong VW; Barker N; Ross AP; Lucassen E; Gufran M; Hu X; Zielman R; Seifer G; Vermersch P
    Mult Scler J Exp Transl Clin; 2023; 9(4):20552173231203816. PubMed ID: 37829441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab.
    Adamec I; Rogić D; Penz MG; Braun C; Habek M
    J Neuroimmunol; 2022 Jan; 362():577788. PubMed ID: 34922128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunocompetence after SARS-CoV-2 Infection in a Patient with Multiple Sclerosis Treated with Ofatumumab: A Case Report.
    Jasińska E
    Case Rep Neurol; 2022; 14(2):320-325. PubMed ID: 36160655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Case of Prolonged Fever in a Patient Infected With COVID-19 on Ofatumumab.
    Uddin Y; Ramirez H; Sheth MA
    Cureus; 2023 Aug; 15(8):e43274. PubMed ID: 37692739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab.
    Flores-Gonzalez RE; Hernandez J; Tornes L; Rammohan K; Delgado S
    Mult Scler Relat Disord; 2021 Apr; 49():102777. PubMed ID: 33508573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life and tolerability of B-cell directed therapy of multiple sclerosis with ofatumumab in a patient-centered real-world observational study.
    Karl AS; Klimas R; Katsimpoura M; Sgodzai M; Theile-Ochel S; Poser PL; Gisevius B; Faissner S; Salmen A; Nastos I; Gold R; Motte J
    J Neurol; 2024 Sep; 271(9):6080-6088. PubMed ID: 39039273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study.
    Kira JI; Nakahara J; Sazonov DV; Kurosawa T; Tsumiyama I; Willi R; Zalesak M; Pingili R; Häring DA; Ramanathan K; Kieseier BC; Merschhemke M; Su W; Saida T
    Mult Scler; 2022 Jul; 28(8):1229-1238. PubMed ID: 34787005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Bar-Or A; Grove RA; Austin DJ; Tolson JM; VanMeter SA; Lewis EW; Derosier FJ; Lopez MC; Kavanagh ST; Miller AE; Sorensen PS
    Neurology; 2018 May; 90(20):e1805-e1814. PubMed ID: 29695594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.
    Bar-Or A; Wiendl H; Montalban X; Alvarez E; Davydovskaya M; Delgado SR; Evdoshenko EP; Giedraitiene N; Gross-Paju K; Haldre S; Herrman CE; Izquierdo G; Karelis G; Leutmezer F; Mares M; Meca-Lallana JE; Mickeviciene D; Nicholas J; Robertson DS; Sazonov DV; Sharlin K; Sundaram B; Totolyan N; Vachova M; Valis M; Bagger M; Häring DA; Ludwig I; Willi R; Zalesak M; Su W; Merschhemke M; Fox EJ
    Mult Scler; 2022 May; 28(6):910-924. PubMed ID: 34605319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.
    Milo R; Staun-Ram E; Karussis D; Karni A; Hellmann MA; Bar-Haim E; Miller A;
    Front Immunol; 2022; 13():868915. PubMed ID: 35432335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.